Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Waycross Partners LLC

Waycross Partners LLC raised its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 11.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,710 shares of the medical equipment provider’s stock after purchasing an additional 5,313 shares during the period. Intuitive Surgical accounts for approximately 3.6% of Waycross Partners LLC’s holdings, making the stock its 7th biggest holding. Waycross Partners LLC’s holdings in Intuitive Surgical were worth $23,448,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of ISRG. Ridgewood Investments LLC acquired a new position in Intuitive Surgical in the second quarter valued at approximately $26,000. Creekmur Asset Management LLC increased its holdings in Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares during the last quarter. LGT Financial Advisors LLC lifted its stake in Intuitive Surgical by 415.4% in the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 54 shares during the period. Delos Wealth Advisors LLC lifted its stake in Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 57 shares during the period. Finally, LRI Investments LLC bought a new position in Intuitive Surgical during the first quarter worth about $30,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 0.8 %

Intuitive Surgical stock opened at $489.86 on Monday. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $496.18. The company has a fifty day simple moving average of $463.74 and a 200 day simple moving average of $422.04. The company has a market cap of $173.75 billion, a P/E ratio of 88.42, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter last year, the company earned $1.18 EPS. Intuitive Surgical’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, equities research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ISRG. Robert W. Baird increased their price target on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research report on Friday, July 19th. Truist Financial increased their target price on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Piper Sandler boosted their price target on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. JPMorgan Chase & Co. upped their price objective on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Finally, Citigroup lifted their target price on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $446.45.

Insiders Place Their Bets

In related news, EVP Robert Desantis sold 238 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $477.50, for a total value of $113,645.00. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,629,115. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, EVP Robert Desantis sold 238 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $477.50, for a total value of $113,645.00. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,629,115. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Gary Loeb sold 300 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $475.00, for a total value of $142,500.00. Following the transaction, the general counsel now directly owns 1,595 shares in the company, valued at approximately $757,625. The disclosure for this sale can be found here. Insiders have sold 50,555 shares of company stock valued at $24,267,737 in the last 90 days. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.